Skip to content

Spyre Therapeutics, Inc. SYRE Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$69.01M-10.4%-$62.53M-459%-$11.18M+69.5%-$36.72M+18.0%-$44.77M+20.5%
$12.81M+30.5%$9.81M+2.6%$9.57M+2.0%$9.38M+5.9%$8.86M-3.9%
-$57.37M-28.7%-$44.58M-20.1%-$37.12M+20.3%-$46.56M-13.6%-$40.99M-10.2%
$56.58M+123%-$247.41M-1,090%$25M-68.4%$79M+129,605%-$61K+100.0%
$12.26M-96.1%$312.81M+6,837%-$4.64M-735%$731K+485%$125K-99.9%
$11.46M-$16.76M-$40.93M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Spyre Therapeutics, Inc. generate?
Spyre Therapeutics, Inc. (SYRE) generated -$185.6M in operating cash flow over the trailing twelve months.
Where does Spyre Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Spyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.